Literature DB >> 22778191

Clinical safety of 1500 mg oral naltrexone overdose.

Albert Stuart Reece1.   

Abstract

This case represents a clinical overdose of the largest known dose of oral naltrexone, equivalent to the taking of a whole bottle of the oral naltrexone preparation. The patient's intention was to control craving for alcohol and opiates. The patient quickly settled with expectant management. As such it demonstrates that earlier concerns that have been voiced in this area, particularly relating to naltrexone-related hepatotoxicity and depression, may have been overstated, at least in the experience of this patient. This patient's course was marked only by gastric irritation, of which she had some history. As such the present profile provides case report evidence consistent with more robust views of the patient safety of naltrexone itself, and opposing more cautious views. Her polydrug craving was suppressed for a period of 2 weeks, which raises the important question of the mechanism of action of naltrexone's generalised suppression of refractory hedonic consumptive addictive behaviours.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22778191      PMCID: PMC3028212          DOI: 10.1136/bcr.04.2010.2871

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  67 in total

1.  Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts.

Authors:  K Miotto; M J McCann; R A Rawson; D Frosch; W Ling
Journal:  Drug Alcohol Depend       Date:  1997-04-14       Impact factor: 4.492

2.  Clinical outcome with naltrexone.

Authors:  R B Resnick; A M Washton
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

Review 3.  The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.

Authors:  A Schecter
Journal:  Am J Drug Alcohol Abuse       Date:  1980       Impact factor: 3.829

Review 4.  Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment.

Authors:  J R Volpicelli; L A Volpicelli; C P O'Brien
Journal:  Alcohol Alcohol       Date:  1995-11       Impact factor: 2.826

5.  Hostility in heroin abusers subtypes: fluoxetine and naltrexone treatment.

Authors:  G Gerra; G Fertonani; A Zaimovic; I Rota-Graziosi; P Avanzini; R Caccavari; R Delsignore; A Lucchini
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1995-12       Impact factor: 5.067

6.  Naltrexone, 6 beta-naltrexol and 2-hydroxy-3-methoxy-6 beta-naltrexol plasma levels in schizophrenic patients after large oral doses of naltrexone.

Authors:  K Verebey; S J Mulé
Journal:  NIDA Res Monogr       Date:  1979

7.  Naltrexone as an adjunctive treatment for older patients with alcohol dependence.

Authors:  D Oslin; J G Liberto; J O'Brien; S Krois; J Norbeck
Journal:  Am J Geriatr Psychiatry       Date:  1997       Impact factor: 4.105

Review 8.  Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine.

Authors:  M S Gold
Journal:  Psychiatr Clin North Am       Date:  1993-03

9.  Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1978-03

10.  Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison.

Authors:  B A Judson; T M Carney; A Goldstein
Journal:  Drug Alcohol Depend       Date:  1981-07       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.